View All Blog Posts

Partnerships Are Bringing Lifesaving Treatments To The Middle East And North Africa

As the world prepares for future public health threats to emerge, it’s imperative public and private sector leaders are collaborating to address these challenges with innovative treatments and solutions.

In the Middle East and North Africa, public-private partnerships between biopharmaceutical companies and other organizations, especially in response to the COVID-19 pandemic, have demonstrated how to effectively treat emerging threats to public health.

In response to the COIVD-19 pandemic, companies have entered into voluntary agreements to allow generic manufacturers to produce treatments and expand patient access. Some examples include:

  • In January 2022, biopharmaceutical manufacturers, including Merck and Hikma Pharmaceuticals in Jordan, signed a licensing agreement with the Medicines Patent Pool (MPP). This agreement allows generic manufacturers to produce Merck’s oral COVID-19 antiviral medication.
  • SaudiVax, a biotechnology company focused on the development of vaccines and biologics, was established to manufacture high quality and affordable vaccines and biopharmaceuticals. In April 2020, drug manufacturer Merck signed a collaborative research agreement with SaudiVax to explore potential vaccinations and treatments for coronaviruses.
  • Gilead entered a voluntary licensing agreement with Eva Pharma in Egypt to increase production of remdesivir.

These partnerships protect the intellectual property (IP) of the innovator while increasing access to treatments.

Continued protection of innovators’ IP is critical for companies to invest in research and development of medicines to treat COVID-19 and address future public health threats. This is why voluntary partnerships are good models to increase patient access to medicines. Collaborations like these support greater access to innovative treatments and medicines without infringing on IP protections, demonstrating that waiving IP rights isn’t necessary.

Resources

Global Investments in Science and Innovation were Resilient during COVID-19

A new report, Global Innovation Index 2022, from the World Intellectual Property Organization (WIPO) indicates that research and development (R&D) investments thrived at the height of the COVID-19 pandemic in 2020 and continued to boom in 2021. This spike in innovation occurred despite the global recession and economic lockdowns in many countries, pointing to the importance of innovation for pandemic solutions and recovery.

The 75th World Health Assembly Comes at a Critical Moment for Health Care in the Middle East

This week, the 75th World Health Assembly (WHA) will convene key leaders from 194 member states in Geneva to discuss some of the most pressing challenges impacting global public health, with this year’s theme focusing on “health for peace and peace for health.” As the COVID-19 pandemic continues to weigh on global public health systems,

Opportunities for Progress

Explore policy-related opportunities for governments, health officials and companies operating in the MENA health sector.

Learn more